Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1−/− mice

Stacey Anne Gould; Matthew White; Anna L. Wilbrey; Erzsébet Pór; Michael Philip Coleman; Robert Adalbert

doi:10.1016/j.expneurol.2021.113607

Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1^−/− mice

Stacey Anne Gould, Matthew White, Anna L. Wilbrey, Erzsébet Pór, Michael Philip Coleman, Robert Adalbert^*

^*Corresponding author for this work

Basic and Clinical Neuroscience

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of cancer treatment, often associated with degeneration of sensory axons or their terminal regions. Presence of the slow Wallerian degeneration protein (WLD^S), or genetic deletion of sterile alpha and TIR motif containing protein 1 (SARM1), which strongly protect axons from degeneration after injury or axonal transport block, alleviate pain in several CIPN models. However, oxaliplatin can cause an acute pain response, suggesting a different mechanism of pain generation. Here, we tested whether the presence of WLD^S or absence of SARM1 protects against acute oxaliplatin-induced pain in mice after a single oxaliplatin injection. In BL/6 and Wld^S mice, oxaliplatin induced significant mechanical and cold hypersensitivities which were absent in Sarm1^−/− mice. Despite the presence of hypersensitivity there was no significant loss of intraepidermal nerve fibers (IENFs) in the footpads of any mice after oxaliplatin treatment, suggesting that early stages of pain hypersensitivity could be independent of axon degeneration. To identify other changes that could underlie the pain response, RNA sequencing was carried out in DRGs from treated and control mice of each genotype. Sarm1^−/− mice had fewer gene expression changes than either BL/6 or Wld^S mice. This is consistent with the pain measurements in demonstrating that Sarm1^−/⁻ DRGs remain relatively unchanged after oxaliplatin treatment, unlike those in BL/6 and Wld^S mice. Changes in levels of four transcripts – Alas2, Hba-a1, Hba-a2, and Tfrc – correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes. Our findings suggest that targeting SARM1 could be a viable therapeutic approach to prevent oxaliplatin-induced acute neuropathic pain.

Original language	English
Article number	113607
Journal	Experimental Neurology
Volume	338
DOIs	https://doi.org/10.1016/j.expneurol.2021.113607
Publication status	Published - Apr 2021

Keywords

Axon degeneration
Cold hypersensitivity
Mechanical hypersensitivity
Neuropathic pain
Oxaliplatin
SARM1
WLD

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.expneurol.2021.113607

Cite this

@article{9b33cf0b6b6a42fa96280af6b3a4bb89,

title = "Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1−/− mice",

abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of cancer treatment, often associated with degeneration of sensory axons or their terminal regions. Presence of the slow Wallerian degeneration protein (WLDS), or genetic deletion of sterile alpha and TIR motif containing protein 1 (SARM1), which strongly protect axons from degeneration after injury or axonal transport block, alleviate pain in several CIPN models. However, oxaliplatin can cause an acute pain response, suggesting a different mechanism of pain generation. Here, we tested whether the presence of WLDS or absence of SARM1 protects against acute oxaliplatin-induced pain in mice after a single oxaliplatin injection. In BL/6 and WldS mice, oxaliplatin induced significant mechanical and cold hypersensitivities which were absent in Sarm1−/− mice. Despite the presence of hypersensitivity there was no significant loss of intraepidermal nerve fibers (IENFs) in the footpads of any mice after oxaliplatin treatment, suggesting that early stages of pain hypersensitivity could be independent of axon degeneration. To identify other changes that could underlie the pain response, RNA sequencing was carried out in DRGs from treated and control mice of each genotype. Sarm1−/− mice had fewer gene expression changes than either BL/6 or WldS mice. This is consistent with the pain measurements in demonstrating that Sarm1−/− DRGs remain relatively unchanged after oxaliplatin treatment, unlike those in BL/6 and WldS mice. Changes in levels of four transcripts – Alas2, Hba-a1, Hba-a2, and Tfrc – correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes. Our findings suggest that targeting SARM1 could be a viable therapeutic approach to prevent oxaliplatin-induced acute neuropathic pain.",

keywords = "Axon degeneration, Cold hypersensitivity, Mechanical hypersensitivity, Neuropathic pain, Oxaliplatin, SARM1, WLD",

author = "Gould, {Stacey Anne} and Matthew White and Wilbrey, {Anna L.} and Erzs{\'e}bet P{\'o}r and Coleman, {Michael Philip} and Robert Adalbert",

note = "Funding Information: This work was supported by the United Kingdom Medical Research Council project grant ( MR/L003813/1 ); Biotechnology and Biological Sciences Research Council Institute Strategic Programme Grant ; and the John and Lucille van Geest Foundation . Publisher Copyright: {\textcopyright} 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = apr,

doi = "10.1016/j.expneurol.2021.113607",

language = "English",

volume = "338",

journal = "Experimental Neurology",

issn = "0014-4886",

publisher = "ACADEMIC PRESS INC",

}

TY - JOUR

T1 - Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1−/− mice

AU - Gould, Stacey Anne

AU - White, Matthew

AU - Wilbrey, Anna L.

AU - Pór, Erzsébet

AU - Coleman, Michael Philip

AU - Adalbert, Robert

N1 - Funding Information: This work was supported by the United Kingdom Medical Research Council project grant ( MR/L003813/1 ); Biotechnology and Biological Sciences Research Council Institute Strategic Programme Grant ; and the John and Lucille van Geest Foundation . Publisher Copyright: © 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/4

Y1 - 2021/4

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of cancer treatment, often associated with degeneration of sensory axons or their terminal regions. Presence of the slow Wallerian degeneration protein (WLDS), or genetic deletion of sterile alpha and TIR motif containing protein 1 (SARM1), which strongly protect axons from degeneration after injury or axonal transport block, alleviate pain in several CIPN models. However, oxaliplatin can cause an acute pain response, suggesting a different mechanism of pain generation. Here, we tested whether the presence of WLDS or absence of SARM1 protects against acute oxaliplatin-induced pain in mice after a single oxaliplatin injection. In BL/6 and WldS mice, oxaliplatin induced significant mechanical and cold hypersensitivities which were absent in Sarm1−/− mice. Despite the presence of hypersensitivity there was no significant loss of intraepidermal nerve fibers (IENFs) in the footpads of any mice after oxaliplatin treatment, suggesting that early stages of pain hypersensitivity could be independent of axon degeneration. To identify other changes that could underlie the pain response, RNA sequencing was carried out in DRGs from treated and control mice of each genotype. Sarm1−/− mice had fewer gene expression changes than either BL/6 or WldS mice. This is consistent with the pain measurements in demonstrating that Sarm1−/− DRGs remain relatively unchanged after oxaliplatin treatment, unlike those in BL/6 and WldS mice. Changes in levels of four transcripts – Alas2, Hba-a1, Hba-a2, and Tfrc – correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes. Our findings suggest that targeting SARM1 could be a viable therapeutic approach to prevent oxaliplatin-induced acute neuropathic pain.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of cancer treatment, often associated with degeneration of sensory axons or their terminal regions. Presence of the slow Wallerian degeneration protein (WLDS), or genetic deletion of sterile alpha and TIR motif containing protein 1 (SARM1), which strongly protect axons from degeneration after injury or axonal transport block, alleviate pain in several CIPN models. However, oxaliplatin can cause an acute pain response, suggesting a different mechanism of pain generation. Here, we tested whether the presence of WLDS or absence of SARM1 protects against acute oxaliplatin-induced pain in mice after a single oxaliplatin injection. In BL/6 and WldS mice, oxaliplatin induced significant mechanical and cold hypersensitivities which were absent in Sarm1−/− mice. Despite the presence of hypersensitivity there was no significant loss of intraepidermal nerve fibers (IENFs) in the footpads of any mice after oxaliplatin treatment, suggesting that early stages of pain hypersensitivity could be independent of axon degeneration. To identify other changes that could underlie the pain response, RNA sequencing was carried out in DRGs from treated and control mice of each genotype. Sarm1−/− mice had fewer gene expression changes than either BL/6 or WldS mice. This is consistent with the pain measurements in demonstrating that Sarm1−/− DRGs remain relatively unchanged after oxaliplatin treatment, unlike those in BL/6 and WldS mice. Changes in levels of four transcripts – Alas2, Hba-a1, Hba-a2, and Tfrc – correlated with oxaliplatin-induced pain, or absence thereof, across the three genotypes. Our findings suggest that targeting SARM1 could be a viable therapeutic approach to prevent oxaliplatin-induced acute neuropathic pain.

KW - Axon degeneration

KW - Cold hypersensitivity

KW - Mechanical hypersensitivity

KW - Neuropathic pain

KW - Oxaliplatin

KW - SARM1

KW - WLD

UR - http://www.scopus.com/inward/record.url?scp=85099830967&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2021.113607

DO - 10.1016/j.expneurol.2021.113607

M3 - Article

C2 - 33460644

AN - SCOPUS:85099830967

SN - 0014-4886

VL - 338

JO - Experimental Neurology

JF - Experimental Neurology

M1 - 113607

ER -